Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

ISRG.NASDAQ

Intuitive Surgical

Healthcare | Medical Instruments & Supplies

Robotic-assisted surgery company known for the da Vinci Surgical System and minimally invasive procedure platforms.

Flagship Insight

Why This High-Multiple Medical Technology Giant Faces A Hidden Valuation Gravity

There is high consensus that this medical robotics leader possesses an exceptional recurring revenue model and a pristine balance sheet. However, sharp divergence exists regarding near-term valuation multiple compression under restrictive monetary policy, as high interest rates threaten hospital capital budgets and pharmaceutical innovations pressure bariatric procedure volumes.

Forecast TimelineUpdated On Jul 02 2026

Intuitive Surgical (ISRG) Stock Forecast and AI Rating

Recommendation

Small Buy

Open a small position; wait before adding more.

2027

1-Year

BUY

$454

+6.5%

+28% IF INCL. DIVS

2029

3-Year

N/A

$573

+64%

2031

5-Year

BUY

$726

+70%

+107% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The core investment thesis centers on a classic value-ownership dilemma: a fundamentally exceptional business trading at an extreme valuation multiple that leaves no margin of safety. While the rollout of the next-generation platform and a highly resilient razor-and-blade recurring revenue model will drive robust mid-teens earnings expansion, these gains are likely to be diluted by multiple contraction in a sticky-rate, capital-constrained macro regime. Professional quants must balance near-term multiple gravity against long-term AI-data compounding.

Key insights

The recurring revenue engine, comprising approximately eighty percent of sales, provides a highly visible and durable cash flow floor.
The next-generation platform rollout initiates a multi-year upgrade cycle, deepening hospital switching costs and surgeon lock-in.
A pristine, zero-debt balance sheet insulates the firm from credit-market stress and provides immense capital allocation optionality.
Valuation multiple compression acts as a heavy anchor, as a fifty-times multiple faces mechanical gravity under restrictive rates.
GLP-1 adoption presents a structural, partially unpriced headwind to bariatric procedure volumes, though offset by multi-platform expansion.
The proprietary kinesthetic telemetry dataset establishes an insurmountable moat, transitioning the long-term narrative toward physical AI infrastructure.
Tactical capital allocation, including aggressive share repurchases, establishes a structural valuation floor during periods of macro-driven volatility.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Intuitive Surgical quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Intuitive Surgical.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$391.93	$423.17	$447.31	$736.09
Quarter 2+6M	Jan 02, 2027	$372.33	$433.12	$474.15	$724.14
Quarter 3+9M	Apr 02, 2027	$357.44	$436.12	$479.16	$713.57
Quarter 4+1Y	Jul 02, 2027	$371.74	$449.38	$487.05	$723.38
Quarter 5+15M	Oct 02, 2027	$390.32	$453.65	$488.36	$716.61
Quarter 6+18M	Jan 02, 2028	$404.35	$472.53	$517.66	$738.34
Quarter 7+21M	Apr 02, 2028	$420.53	$482.63	$528.16	$746.91
Quarter 8+2Y	Jul 02, 2028	$428.94	$503.58	$544.94	$771.93
Quarter 9+27M	Oct 02, 2028	$420.36	$513.82	$561.29	$782.73
Quarter 10+30M	Jan 02, 2029	$441.38	$530.60	$588.29	$807.31
Quarter 11+33M	Apr 02, 2029	$454.62	$544.36	$605.93	$822.72
Quarter 12+3Y	Jul 02, 2029	$450.07	$560.66	$628.37	$846.10
Quarter 13+39M	Oct 02, 2029	$468.08	$573.32	$630.21	$852.53
Quarter 14+42M	Jan 02, 2030	$482.12	$599.89	$655.42	$882.91
Quarter 15+45M	Apr 02, 2030	$472.48	$614.51	$678.39	$900.46
Quarter 16+4Y	Jul 02, 2030	$481.93	$626.71	$723.73	$922.67
Quarter 17+51M	Oct 02, 2030	$496.38	$651.26	$747.86	$935.91
Quarter 18+54M	Jan 02, 2031	$516.24	$683.94	$807.69	$952.30
Quarter 19+57M	Apr 02, 2031	$511.08	$699.67	$831.92	$976.28
Quarter 20+5Y	Jul 02, 2031	$526.41	$725.85	$865.19	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's mischaracterization of the business model and its valuation arithmetic. While the crowd analyzes the firm as a cyclical hardware manufacturer vulnerable to hospital capital expenditure budgets, it is actually an unregulated utility and applied AI platform. Approximately eighty percent of revenue is recurring consumable spend tied directly to inelastic procedure volumes, which insulates cash flows from macro capex freezes. Furthermore, the market misprices the immense option value of the proprietary kinesthetic telemetry dataset, which forms an unreproducible training ground for autonomous surgery. Conversely, the crowd ignores the near-term multiple compression risk under a restrictive monetary regime, expecting flawless execution to sustain an elevated multiple when mathematical gravity dictates a valuation reset.

Advisor Disagreement

The primary disagreements across the reports center on the severity of near-term multiple compression and the velocity of the next-generation upgrade cycle. Some perspectives assume that hospital capital constraints and high interest rates will severely delay system placements, forcing a painful multiple contraction toward historical averages. Other views argue that the platform's labor-saving efficiency makes it non-discretionary, allowing the upgrade cycle to defy macro headwinds. Additionally, there is minor disagreement regarding the long-term threat of pharmaceutical weight-loss drugs on overall procedure volumes, with some modeling permanent structural demand destruction and others viewing it as a temporary narrative overhang.

Financial Reviews by iPulse AI

Earnings and financials

The financial reports paint a picture of a highly profitable business operating at peak performance. Recent annual revenues have surged past ten billion dollars, growing at over twenty percent year-over-year, while net margins remain exceptionally strong at around twenty-eight percent. The assessments strongly agree that the company's financial engine is incredibly healthy, driven by a highly reliable stream of recurring revenue from surgical supplies. However, there is a clear clash regarding how this growth will translate to stock performance. Some views warn that because the stock is currently priced so high, future stock returns will lag behind the company's actual business growth due to inevitable valuation adjustments. Others remain highly confident that the sheer force of cash flow compounding and aggressive share buybacks will easily overcome these valuation hurdles, making it a safe-haven asset for long-term investors.

Profitability and margins

The company maintains exceptionally high and stable profit margins, with gross margins locked near sixty-seven percent and operating margins hovering around twenty-nine percent. This incredible profitability is driven by the company's highly successful business model, where hospitals must continuously purchase proprietary, high-margin instruments for every surgery performed. The reports agree that these margins reflect immense pricing power and a deeply entrenched customer base. However, opinions clash regarding the future direction of these margins. Some views suggest that operating margins will expand further toward thirty-five percent as high-margin software and artificial intelligence subscriptions are introduced. Conversely, other assessments caution that rising raw material costs, global supply chain disruptions, and the arrival of cheaper competitor systems could put downward pressure on margins, making the stock's expensive valuation multiple highly sensitive to any potential profit slips.

Balance sheet and leverage

The company's balance sheet is described as an impenetrable financial fortress, boasting over twenty billion dollars in total assets and virtually zero debt. The reports are in absolute agreement that this debt-free structure makes the company completely safe from rising interest rates, credit tightening, and refinancing risks. In a difficult economic climate where heavily indebted competitors are struggling to survive, this financial safety acts as a powerful shield. Furthermore, it provides management with immense flexibility to play offense. The company can easily fund its own research, offer flexible leasing terms to cash-strapped hospitals, and execute massive multi-billion-dollar share buybacks to support the stock price. There are no major disagreements on this front; the company's financial safety and firepower are considered world-class, offering investors ultimate peace of mind.

Capex and investment intensity

The company operates with a highly efficient, capital-light business model that is a massive advantage in today's high-interest-rate environment. Traditional spending on physical buildings and equipment is very low, hovering around five percent of revenue, as hospitals bear the primary cost of installing the machines. Instead, the company heavily concentrates its spending on research and development, investing over one billion dollars annually to fund next-generation platforms and advanced software. The reports agree that this disciplined spending generates spectacular returns on invested capital and keeps the company far ahead of its rivals. While some analysts suggest monitoring potential short-term costs related to manufacturing rollouts, the consensus is clear: the company's ability to self-fund its technological future without borrowing expensive money makes it an incredibly strong and safe investment for the long haul.